SciSparc (SPRC) Cash from Financing Activities (2016 - 2018)
SciSparc (SPRC) posted Cash from Financing Activities of $1.6 million for Q4 2018, up 157100.0% sequentially from $1000.0 in Q2 2018, and up 1503.57% YoY from $98031.2 in Q4 2017.
SciSparc (SPRC) Cash from Financing Activities (2016 - 2018) Analysis & Trends
SciSparc has reported Cash from Financing Activities for 3 years, with the latest figure at $1.6 million in Q4 2018.
- Quarterly Cash from Financing Activities rose 1503.57% year-over-year to $1.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.5 million (down 88.34% YoY) and the FY2025 annual result came in at $8.6 million, up 38.67% from the prior year.
- Cash from Financing Activities rose to $1.6 million in Q4 2018 per SPRC's latest filing, from $1000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $11.2 million in Q1 2017 and troughed at -$541000.0 in Q4 2016.
- A 3-year average of $1.7 million and a median of $120000.0 in 2017 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 1503.57% in 2018, down 100.33% in 2018.
- Over 3 years, Cash from Financing Activities stood at -$541000.0 in 2016, then jumped by 79.3% to -$112000.0 in 2017, then surged by 1503.57% to $1.6 million in 2018.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.6 million, $1000.0, and -$37000.0 for Q4 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | SciSparc | 831,418.60 | 831,418.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.57 Mn |
| Dec 31, 2018 | 1.57 Mn |
| Jun 30, 2018 | 1,000.00 |
| Jun 30, 2018 | 1,000.00 |
| Mar 31, 2018 | -37,000.00 |
| Mar 31, 2018 | -37,000.00 |
| Dec 31, 2017 | -112,000.00 |
| Dec 31, 2017 | -112,000.00 |
| Sep 30, 2017 | 120,000.00 |
| Sep 30, 2017 | 120,000.00 |
| Jun 30, 2017 | 1.94 Mn |
| Jun 30, 2017 | 1.94 Mn |
| Mar 31, 2017 | 11.22 Mn |
| Mar 31, 2017 | 11.22 Mn |
| Dec 31, 2016 | -541,000.00 |
| Dec 31, 2016 | -541,000.00 |
| Sep 30, 2016 | 1.11 Mn |
| Sep 30, 2016 | 1.11 Mn |